Document is current
Any future updates will be listed below
-
Authors
,
Todd, Jamie L. https://orcid.org/0000-0003-4247-3693
Vinisko, Richard
Liu, Yi
Neely, Megan L.
Overton, Robert
Flaherty, Kevin R.
Noth, Imre
Newby, L. Kristin
Lasky, Joseph A.
Olman, Mitchell A.
Hesslinger, Christian
Leonard, Thomas B.
Palmer, Scott M.
Belperio, John A.
- License Information
-
More Information
Article History
Received: 29 July 2019
Accepted: 28 February 2020
First Online: 14 March 2020
Ethics approval and consent to participate
: The IPF-PRO Registry study obtained ethics approval at the data coordinating center (Duke Clinical Research Institute, Duke Institutional Review Board Protocol Number Pro00046131) and at every enrolling center (listed in the Acknowledgments). All participants gave written informed consent. Additionally, ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for the analyses contained herein.
: Not applicable.
: JLT, MLN, RO, LKN and SMP are employees of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. to coordinate the IPF-PRO Registry. KRF reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech and personal fees from FibroGen, Sanofi Genzyme, and Veracyte. IN reports personal fees from Boehringer Ingelheim, Genentech and ImmuneWorks. JAL reports personal fees from Boehringer Ingelheim, Roche/Genentech, Galecto, Biogen and Veracyte. MAO reports research grant and grant review fees from Boehringer Ingelheim. RV, KD, YL, CH and TBL are employees of Boehringer Ingelheim. JAB has no competing interests.
